Altis Biosystems, Inc.

Empowering the forefront of biotechnology, Altis Biosystems stands as a leader in innovating preclinical drug discovery in Durham, North Carolina. With a commitment to transforming research and development processes, they offer advanced human intestinal in vitro model systems, creating a paradigm shift in drug testing and therapeutic advancement.

RepliGut® platforms serve as the cornerstone of their offerings, designed to closely mimic human gut physiology. This proprietary technology not only reduces reliance on animal testing but enhances the translation from drug discovery to clinical trials. With solutions like RepliGut® Planar for drug metabolism studies and RepliGut® Immune Co-Culture for modeling gut inflammation, Altis provides essential tools for a variety of research applications.

In addition to their groundbreaking platforms, Altis excels with services such as InflammaScreen™, a rapid anti-inflammatory screening assay, and the RepliGut® StemTox™ assay, known for its high accuracy in predicting gastrointestinal toxicity. These services deliver quick turnaround times and comprehensive readouts, ensuring researchers obtain actionable insights efficiently.

The company also prides itself on its extensive donor biobank, which allows for reproducibility and a wide demographic representation in research. By partnering with international leaders and offering scalable, user-friendly formats, Altis Biosystems is poised to improve the safety and effectiveness of therapeutic developments on a global scale.